SFJ Pharmaceuticals, Inc

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the

Life sciences venture capital major Abingworth is reportedly looking to raise up to $1.5bn in funding to be deployed for clinical development projects partnered with pharma companies in return for fut

Cytokinetics, Inc. CEO Robert Blum has maintained since the company reported positive topline Phase III results for the cardiac myosin inhibitor aficamten in obstructive hypertrophic cardiomyopathy (

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gilead Takes On XinThera’s Preclinical